Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
29 mars 2023 13h41 HE
|
Psycheceutical Bioscience, Inc.
Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical"...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
21 mars 2023 12h50 HE
|
Psycheceutical Bioscience, Inc.
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical...
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
15 févr. 2023 11h30 HE
|
Psycheceutical Bioscience, Inc.
Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical in AustraliaPhase I trial will study 20 people to test the safety, tolerability,...
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
02 févr. 2023 10h20 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery...
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
26 janv. 2023 12h15 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for...
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
10 janv. 2023 14h05 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc.(OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery...
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
29 nov. 2022 11h35 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
Psycheceutical Bioscience, Inc. Announces Medical Advisory Board
18 oct. 2022 10h15 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
04 oct. 2022 10h14 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...
Psycheceutical Bioscience, Inc.'s CEO to Present at the Life Sciences Investor Forum on September 15
13 sept. 2022 11h15 HE
|
Psycheceutical Bioscience, Inc.
MIAMI, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for...